Morgan Stanley
GOSS icon

Morgan Stanley’s Gossamer Bio GOSS Stock Holding History

Morgan Stanley’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.8K Sell
3,020
-1,572
-34% -$35.1K ﹤0.01% 6587
2026
Q1 		$121K Sell
4,592
-6,894
-60% -$867K ﹤0.01% 6075
2025
Q4 		$2.85M Buy
11,486
+4,406
+62% +$1.01M ﹤0.01% 4569
2025
Q3 		$1.49M Sell
7,080
-3,154
-31% -$556K ﹤0.01% 4950
2025
Q2 		$1.01M Buy
10,234
+4,490
+78% +$392K ﹤0.01% 5098
2025
Q1 		$505K Buy
5,744
+3,887
+209% +$359K ﹤0.01% 5318
2024
Q4 		$134K Sell
1,857
-396
-18% -$27.1K ﹤0.01% 5936
2024
Q3 		$178K Sell
2,253
-180
-7% -$13.9K ﹤0.01% 5790
2024
Q2 		$175K Sell
2,433
-51,756
-96% -$3.1M ﹤0.01% 5739
2024
Q1 		$5.12M Sell
54,189
-15,422
-22% -$1.36M ﹤0.01% 3895
2023
Q4 		$5.08M Buy
69,611
+64,719
+1,323% +$3.82M ﹤0.01% 3900
2023
Q3 		$326K Sell
4,892
-2,311
-32% -$213K ﹤0.01% 5355
2023
Q2 		$692K Sell
7,203
-2,420
-25% -$241K ﹤0.01% 5044
2023
Q1 		$970K Sell
9,623
-29,919
-76% -$4.58M ﹤0.01% 4880
2022
Q4 		$6.86M Buy
39,542
+24,447
+162% +$16.1M ﹤0.01% 3458
2022
Q3 		$14.5M Sell
15,095
-2,121
-12% -$2.11M ﹤0.01% 2564
2022
Q2 		$11.5M Buy
17,216
+1,059
+7% +$656K ﹤0.01% 2924
2022
Q1 		$11.2M Buy
16,157
+884
+6% +$682K ﹤0.01% 2785
2021
Q4 		$13.8M Buy
15,273
+12,099
+381% +$11.5M ﹤0.01% 2562
2021
Q3 		$3.19M Sell
3,174
-685
-18% -$504K ﹤0.01% 4163
2021
Q2 		$2.51M Sell
3,859
-253
-6% -$175K ﹤0.01% 4462
2021
Q1 		$3.04M Sell
4,112
-228
-5% -$184K ﹤0.01% 3911
2020
Q4 		$3.36M Buy
4,340
+1,855
+75% +$1.46M ﹤0.01% 3693
2020
Q3 		$2.47M Sell
2,485
-2,251
-48% -$2.39M ﹤0.01% 3462
2020
Q2 		$4.92M Buy
4,736
+2,334
+97% +$2.35M ﹤0.01% 2689
2020
Q1 		$1.95M Buy
2,402
+1,331
+124% +$1.39M ﹤0.01% 3391
2019
Q4 		$1.34M Sell
1,071
-379
-26% -$611K ﹤0.01% 4332
2019
Q3 		$1.95M Buy
1,450
+1,436
+10,257% +$2.28M ﹤0.01% 3817
2019
Q2 		$24K Sell
14
-12
-46% -$18.4K ﹤0.01% 5872
2019
Q1 		$46K Buy
+26
New +$43.4K ﹤0.01% 5707

Other funds holding GOSS

D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DeepCurrents Investment Group
DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
GSA Capital Partners
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM

Morgan Stanley's GOSS Position: Q2 2026 in Review

Morgan Stanley reduced its Gossamer Bio (GOSS) stake by 34% in Q2 2026, selling an estimated $35.1K and leaving 3,020 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6587.

Morgan Stanley first reported a position in GOSS in Q1 2019 and has held it in 30 quarters since. The position peaked at $14.5M in Q3 2022. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Morgan Stanley held 3,020 shares of Gossamer Bio worth $39.8K as of Q2 2026.
  • Morgan Stanley sold 1,572 Gossamer Bio shares in Q2 2026, an estimated $35.1K.
  • Gossamer Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6587 holding.
  • Morgan Stanley first reported a position in Gossamer Bio in Q1 2019 and has held it in 30 quarters since.
  • Morgan Stanley's Gossamer Bio position peaked at $14.5M in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.